Navidea biopharmaceuticals provides statement on covid-19 pandemic

Navidea biopharmaceuticals provides statement regarding covid-19 pandemic.navidea biopharmaceuticals - on track to deliver interim data from arm 3 of phase 2b clinical trial (nav3-31) in timeframe previously communicated.navidea biopharmaceuticals - nav3-33 trial, pivotal phase 3 trial for rheumatoid arthritis, remains on track for a second-half 2020 launch.navidea biopharmaceuticals inc - analysis of data from company's cardiovascular phase 2b study remains on track.
NAVB Ratings Summary
NAVB Quant Ranking